{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:17:25Z","timestamp":1772839045397,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Italian Ministry of Health","award":["National Centre for Disease Prevention and Control, Fasc. 3M58"],"award-info":[{"award-number":["National Centre for Disease Prevention and Control, Fasc. 3M58"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12985-015-0414-1","type":"journal-article","created":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T11:04:50Z","timestamp":1447499090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-na\u00efve patients with chronic hepatitis C"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2897-3595","authenticated-orcid":false,"given":"Angela","family":"Costantino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enea","family":"Spada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Equestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Tritarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Sagnelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelista","family":"Sagnelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rita","family":"Ciccaglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,14]]},"reference":[{"key":"414_CR1","unstructured":"World Healt Org: Hepatitis C fact sheet N\u00b0 164. June 2011 available from http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ ."},{"key":"414_CR2","first-page":"1","volume":"369","author":"P Simmonds","year":"2013","unstructured":"Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol. 2013;369:1\u201315.","journal-title":"Curr Top Microbiol Immunol"},{"key":"414_CR3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","volume":"17","author":"D Lavanchy","year":"2011","unstructured":"Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107\u201315.","journal-title":"Clin Microbiol Infect"},{"key":"414_CR4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCG.0b013e318030e3ab","volume":"42","author":"P Fabris","year":"2008","unstructured":"Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, et al. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol. 2008;42:527\u201332.","journal-title":"J Clin Gastroenterol"},{"key":"414_CR5","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1038\/ajg.2009.428","volume":"104","author":"R Cozzolongo","year":"2009","unstructured":"Cozzolongo R, Osella AR, Elba S, Petruzzi J, Buongiorno G, Giannuzzi V, et al. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol. 2009;104:2740\u201346.","journal-title":"Am J Gastroenterol"},{"key":"414_CR6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.dld.2012.10.014","volume":"45","author":"V Guadagnino","year":"2013","unstructured":"Guadagnino V, Stroffolini T, Caroleo B, Menniti Ippolito F, Rapicetta M, Ciccaglione AR, et al. Hepatitis C virus infection in an endemic area of Southern Italy 14\u00a0years later: evidence for a vanishing infection. Dig and Liver Dis. 2013;45:403\u20137.","journal-title":"Dig and Liver Dis"},{"key":"414_CR7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.meegid.2014.06.006","volume":"26","author":"N Marascio","year":"2014","unstructured":"Marascio N, Ciccozzi M, Equestre M, Lo Presti A, Costantino A, Cella E, et al. Back to the origin of HCV 2c subtype and spreading to the Calabria region (Southern Italy) over the last two centuries: a phylogenetic study. Infect Genet Evol. 2014;26:352\u20138.","journal-title":"Infect Genet Evol"},{"key":"414_CR8","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/jmv.23384","volume":"84","author":"M Ciccozzi","year":"2012","unstructured":"Ciccozzi M, Equestre M, Costantino A, Marascio N, Quirino A, Lo Presti A, et al. Hepatitis C virus genotype 4d in Southern Italy: reconstruction of its origin and spread by a phylodynamic analysis. J Med Virol. 2012;84:1613\u20139.","journal-title":"J Med Virol"},{"key":"414_CR9","unstructured":"EASL ( 2011): 46th annual congress, March 30 - April 3, 2011 available from http:\/\/www.hepmag.com\/archive\/currentNews_2596.shtml ."},{"key":"414_CR10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","volume":"58","author":"A Aghemo","year":"2013","unstructured":"Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatol. 2013;58:428\u201338.","journal-title":"Hepatol"},{"key":"414_CR11","doi-asserted-by":"crossref","unstructured":"Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015 Jun 17. doi: 10.1111\/jvh.12422","DOI":"10.1111\/jvh.12422"},{"key":"414_CR12","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","volume":"88","author":"N Ogata","year":"1991","unstructured":"Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A. 1991;88:3392\u20136.","journal-title":"Proc. Natl. Acad. Sci U S A"},{"key":"414_CR13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","volume":"55","author":"P Halfon","year":"2011","unstructured":"Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55:192\u2013206.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"414_CR14","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/infdis\/jis761","volume":"207","author":"DL Wyles","year":"2013","unstructured":"Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013;207 Suppl 1:S33\u20139.","journal-title":"J Infect Dis."},{"key":"414_CR15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","volume":"46","author":"TL Kieffer","year":"2007","unstructured":"Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatol. 2007;46:631\u201339.","journal-title":"Hepatol"},{"key":"414_CR16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzen S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterol. 2010;138:447\u201362.","journal-title":"Gastroenterol"},{"key":"414_CR17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","volume":"10","author":"S Paolucci","year":"2013","unstructured":"Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J. 2013;10:355.","journal-title":"Virol J"},{"key":"414_CR18","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","volume":"87","author":"DJ Bartels","year":"2013","unstructured":"Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-Na\u00efve patients prior to treatment. J Virol. 2013;87:1544\u201353.","journal-title":"J Virol"},{"key":"414_CR19","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","volume":"48","author":"T Kuntzen","year":"2008","unstructured":"Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistence mutations to hepatitis c virus protease and polymerase inhibitors in treatment-na\u00efve patients. Hepatol. 2008;48:1769\u201378.","journal-title":"Hepatol"},{"key":"414_CR20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3851\/IMP2821","volume":"20","author":"TL Applegate","year":"2015","unstructured":"Applegate TL, Gaudieri S, Plauzolles A, Chopra A, Grebely J, Lucas M, et al. Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C. Antivir Ther. 2015;20:199\u2013208.","journal-title":"Antivir Ther"},{"key":"414_CR21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/135965350801300413","volume":"13","author":"FX L\u00f3pez-Labrador","year":"2008","unstructured":"L\u00f3pez-Labrador FX, Moya A, Gonz\u00e0lez-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3\/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther. 2008;13:481\u201394.","journal-title":"Antivir Ther"},{"key":"414_CR22","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","volume":"54","author":"O Lenz","year":"2010","unstructured":"Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, et al. In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54:1878\u201387.","journal-title":"Antimicrob Agents Chemother"},{"key":"414_CR23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1743-422X-9-245","volume":"9","author":"S Paolucci","year":"2012","unstructured":"Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J. 2012;9:245.","journal-title":"Virol J"},{"key":"414_CR24","first-page":"198940","volume":"21","author":"S Wu","year":"2013","unstructured":"Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol. 2013;21:198940\u20138.","journal-title":"World J Gastroenterol"},{"key":"414_CR25","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","volume":"56","author":"AM Lam","year":"2012","unstructured":"Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56:3359\u201368.","journal-title":"Antimicrob Agents Chemother"},{"key":"414_CR26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","volume":"368","author":"EJ Gane","year":"2013","unstructured":"Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34\u201344.","journal-title":"N Engl J Med"},{"key":"414_CR27","doi-asserted-by":"crossref","unstructured":"Hedskog C, Dvory-Sobol H, Gontcharova V, Martin R, Ouyang W, Han B, et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat. 2015 Mar 18. doi: 10.1111\/jvh.12405 .","DOI":"10.1111\/jvh.12405"},{"key":"414_CR28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","volume":"209","author":"X Tong","year":"2014","unstructured":"Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, et al. In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014;209:668\u201375.","journal-title":"J Infect Dis"},{"key":"414_CR29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","volume":"61","author":"EF Donaldson","year":"2015","unstructured":"Donaldson EF, Harrington PR, O' Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatol. 2015;61:56\u201365.","journal-title":"Hepatol"},{"key":"414_CR30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3851\/IMP1900","volume":"16","author":"S Vallet","year":"2011","unstructured":"Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, et al. NS3 protease polymorphism and natural resistence to protease inhibitors in French patients infected with HCV genotype 1\u20135. Antiviral Therpy. 2011;16:1093\u2013102.","journal-title":"Antiviral Therpy"},{"key":"414_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2014.12.037","volume":"477","author":"H Ji","year":"2015","unstructured":"Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB, et al. Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virol. 2015;477:1\u20139.","journal-title":"Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-015-0414-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T04:21:28Z","timestamp":1653538888000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.virologyj.com\/content\/12\/1\/186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,14]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1186\/s12985-015-0414-1","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,14]]},"article-number":"186"}}